Metastatic Merkel Cell Carcinoma Clinical Trial
Official title:
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04261855 -
Targeted Therapy and Avelumab in Merkel Cell Carcinoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03816332 -
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
|
Phase 1 | |
Recruiting |
NCT05947500 -
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
|
Phase 2 | |
Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03304639 -
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05896839 -
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
|
Phase 1/Phase 2 | |
Approved for marketing |
NCT03089658 -
Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
|